Keytruda (pembrolizumab): a deep-dive

What it is. Keytruda is Merck & Co.’s (MSD outside the US/Canada) humanized IgG4 monoclonal antibody that blocks PD-1, releasing an immune “brake” so T-cells can attack cancer. In the EU it’s authorized—alone and in combinations—across a very broad slate of tumors (NSCLC, melanoma, RCC, urothelial, HNSCC, MSI-H/dMMR cancers, gastric/GEJ, oesophageal, cervical, TNBC, biliary tract, malignant pleural mesothelioma, Hodgkin lymphoma, etc.). European Medicines Agency (EMA)

Who developed it? Who holds the patents?

Developer/MAH: Merck & Co., Inc. (marketing: Merck Sharp & Dohme, “MSD” in EU). European Medicines Agency (EMA)
Core inventions: Composition-of-matter patents covering anti-PD-1 antibodies that block PD-1/PD-L1 binding (e.g., US 8,354,509 B2) and later formulation patents covering the marketed liquid product. Google PatentsEPO
- The EPO Board of Appeal confirmed that a Merck (MSD) patent claims the liquid formulation corresponding to the marketed Keytruda product. EPO

When do the key patents/exclusivities expire?

Patent/exclusivity dates differ by country and patent family. The most cited “cliff” refers to the US core patents, while Europe benefits from SPC (Supplementary Protection Certificate) extensions:

United States: Merck has stated Keytruda’s key patents expire in 2028 (the widely referenced US “patent cliff”), even though some later-filed patents extend beyond that. STAT FirstWord Pharma Barron’s
European Union (major markets): SPCs extend protection to January 2031. WHO
Japan: Key patents expire in 2032. WHO

Why ranges vary: biologics often have multiple overlapping patents (antibody sequences, formulations, dosing, devices) and, in Europe/Japan, SPC or PTE can add years beyond the base 20-year term. EPO

What are the pros?

Broad, high-impact efficacy across cancers. Keytruda has shown survival benefits in many tumor types and disease settings (metastatic, neoadjuvant/adjuvant). The EU label reflects this breadth, including tissue-agnostic approvals for MSI-H/dMMR tumors. European Medicines Agency (EMA)
Durable responses in subsets. Immunotherapy responses, when achieved, can be long-lasting compared with many cytotoxic regimens (seen across multiple labeled indications in the EPAR/SmPC). European Medicines Agency (EMA)
Flexible dosing and combinations. Authorized as monotherapy (e.g., PD-L1–high NSCLC) or in combinations (e.g., with chemo, TKIs like axitinib/lenvatinib, or antibody-drug conjugates such as enfortumab vedotin), with 200 mg q3w or 400 mg q6w schedules. European Medicines Agency (EMA)

What are the cons/limitations?

Immune-related toxicities (irAEs). By design, PD-1 blockade can lead to multi-organ auto-inflammation (see “Safety concerns” below). Management often requires steroids and interruptions or permanent discontinuation. European Medicines Agency (EMA)
Biomarker dependence & resistance. Benefit can be concentrated in PD-L1–expressing or MSI-H/dMMR tumors; many patients with low PD-L1 or mismatch-repair–proficient disease respond less or require combinations—raising toxicity and cost. (Biomarker-linked indications are explicit in the EU label.) European Medicines Agency (EMA)
Cost/exclusivity. As a flagship biologic with extended IP/SPC protection, therapy is expensive, and access can vary by health-system reimbursement. (The extended EU SPC timing underscores exclusivity longevity.) WHO
Complex safety in combinations. Pairing with chemo, TKIs (axitinib/lenvatinib), or ADCs increases adverse-event burden versus monotherapy. European Medicines Agency (EMA)

Safety concerns observed in clinical trials (from the EU SmPC/EPAR)

Overall profile: “Pembrolizumab is most commonly associated with immune-mediated adverse reactions.” Frequencies vary by regimen; fatigue, diarrhea and nausea are common. Serious events include severe irAEs and severe infusion reactions. European Medicines Agency (EMA)

Selected immune-mediated AEs and actions (all from SmPC management tables/text):

Pneumonitis, colitis, hepatitis, nephritis, endocrinopathies (hypo/hyper-thyroidism, adrenal insufficiency, hypophysitis, type 1 diabetes): hold or permanently discontinue per grade; initiate corticosteroids. European Medicines Agency (EMA)
Severe skin reactions: SJS/TEN reported—withhold if suspected; permanently discontinue if confirmed. European Medicines Agency (EMA)
Neurologic/cardiac irAEs: myocarditis, encephalitis, Guillain-Barré syndrome—permanently discontinue for Grade 3–4. European Medicines Agency (EMA)
Other reported irAEs: uveitis, arthritis/myositis, pancreatitis, haemolytic anaemia, sarcoidosis, myelitis/meningitis, vasculitis, sclerosing cholangitis, cystitis, hypoparathyroidism, pericarditis (seen in studies or post-marketing). European Medicines Agency (EMA)
Infusion reactions: severe reactions warrant permanent discontinuation. European Medicines Agency (EMA)

Combination-specific signal examples (label):
With chemo/chemoradiation or with axitinib/lenvatinib, hematologic toxicities, hypertension, hepatic enzyme elevations, GI inflammation and renal AEs increase in frequency; immune-mediated events still occur and require the same interrupt/stop/steroid algorithms. European Medicines Agency (EMA)

Clinically, irAEs can occur during treatment or after discontinuation; prompt recognition and steroid management are essential. The SmPC provides detailed grade-based algorithms and cautions on re-challenge. European Medicines Agency (EMA)

Bottom line

Keytruda transformed oncology by making PD-1 blockade a backbone across dozens of indications, with tissue-agnostic approvals and survival gains in many settings. Its limitations are the flip side of immune activation—multi-organ irAEs—and the need for biomarkers/combos in less inflamed tumors. From an IP standpoint, Merck’s core US patents are expected to roll off in 2028, while EU SPCs extend out to January 2031 and Japan to 2032, after which broader biosimilar competition is expected—though additional formulation/device patents may still shape actual entry. STAT FirstWord Pharma Barron’s WHO

Sources

EU product information (SmPC/EPAR) for Keytruda – indications, dosing, and detailed safety/irAE management. European Medicines Agency (EMA)+1
US composition patent example (US 8,354,509 B2) and EPO Board of Appeal decision linking a Merck patent to the marketed liquid formulation. Google Patents EPO
Patent expiry timing from authoritative overviews (Merck statements as cited in filings/coverage; WHO report summarizing US/EU/Japan dates including SPC). STAT FirstWord Pharma Barron’s WHO

If you’d like, I can tailor a one-page brief for clinicians (with irAE management table) or a payer-focused summary (with timelines for expected biosimilar entry).

Discover more from सुदर्शन

Subscribe to get the latest posts sent to your email.